NEWS

Written By: Todd Murphree, PharmD Clearview Cancer Institute Download Here Description of PQI: Ruxolitinib is a selective Jak2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy. Background: Ruxolitinib is FDA approved for the treatment […]

Written by: Lauren Held, PharmD, BCOP – Seattle Cancer Care Alliance Download Here Copanlisib is an intravenous (IV) phosphatidylinositol 3-kinase (PI3K) inhibitor indicated for the treatment of relapsed follicular lymphoma (FL) in patients that have received at least two prior systemic therapies.1 This PQI will review how to manage select toxicities associated with copanlisib.

Written By: Chris Sellers, RPh, Texas Oncology Download Here Description: The purpose of this PQI is to provide information on the management of common adverse events, follow-up with patients, and dose modifications. Dose adjustments are common and greatly reduced frequency and severity of adverse reactions. In Lux-Lung 3, 43% maintained the 40 mg starting dose, […]

Written by: Kayla Randle, PharmD, BCPS, BCOP, Kaiser Permanente Georgia Oncology Download Here  Description: The purpose of this PQI is to identify differentiating characteristics which would indicate zanubrutinib as a preferred treatment option in Mantle Cell Lymphoma as well as discussing key counseling and monitoring criteria to improve patient outcomes. Background: Zanubrutinib is a potent, highly specific, and […]

Written by: Kirollos S. Hanna, PharmD, BCPS, BCOP – University of Minnesota Medical Center & Mayo Clinic Download Here Description: This PQI will discuss optimal prevention and control of chemotherapy induced nausea and vomiting (CINV) which has been associated with improved adherence to oncolytic therapy. Background: CINV remains one of the most debilitating toxicities associated […]

Written By: Natasha Khrystolubova, RPh, BCOP, Florida Cancer Specialists and Jody Agena, PharmD, Virginia Cancer Specialists Download Here This PQI is intended to address effective practices for the management of alpelisib induced hyperglycemia by focusing on a multidisciplinary approach. Background: Alpelisib (in combination with fulvestrant) is indicated for the treatment of HR-positive, HER2-negative, PIK3CA-mutated, advanced […]

Written by: Andrea Clarke, PharmD and Becky Fahrenbruch, PharmD, BCOP Download Here Description: Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect that can occur with chemotherapeutics, including certain oral chemotherapy agents. Appropriate patient education and monitoring may assist with identifying early signs of peripheral neuropathy, but no agents have demonstrated efficacy in preventing CIPN. […]

Written by Julianne Orr, PharmD, Indiana University Health Simon Cancer Center Download Here Description: Olanzapine is an FDA approved atypical antipsychotic that blocks multiple neuronal receptors involved in nausea/vomiting pathways.1 Olanzapine has been studied for breakthrough2 chemotherapy induced nausea and vomiting (CINV) as well as prophylaxis of highly and moderately emetogenic regimens.3,4,5 Additionally, olanzapine has […]

Written by: Tammy McClellan, PharmD, Riverside Healthcare Download Here Description: The purpose of this PQI is to assess the individualized characteristics of the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patient and important screening measures in order to achieve optimal pharmacological therapy. Background: CLL/SLL, a type of non-Hodgkin Lymphoma, is an indolent cancer in which immature […]

Written by: Kirollos Hanna, PharmD, BCPS, BCOP, University of Minnesota Medical Center & Mayo Clinic Download Here Description: Ixazomib is an oral proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy. This PQI highlights the management, safety, and efficacy of ixazomib. Background: Multiple […]

Written By: Marko Skelin MPharm PhD, Assistant Professor, Faculty of Medicine, University of Rijeka Luis Raez, MD, FACP, Memorial Cancer Institute/Memorial Health Care System DOWNLOAD HERE Description: The purpose of this PQI is to discuss the option of using cemiplimab-rwlc for patients with: Locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) previously treated with […]

Bristol Myers Squibb has developed a 120-mg/12-mL vial. This vial is available in addition to the current vial sizes (40 mg, 100 mg, and 240 mg). For NDC codes and OPDIVO storage information, see the vial flashcard HERE. Please ensure the 120-mg vial is included in your EHR for prescribing. If you need help adding […]